Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Incyte Corporation
  6. Summary
    INCY   US45337C1027

INCYTE CORPORATION

(INCY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/11/2021 05/12/2021 05/13/2021 05/14/2021 05/17/2021 Date
80.64(c) 82.37(c) 83.23(c) 82.62(c) 82.17 Last
2 845 576 1 262 773 960 544 889 201 840 560 Volume
-0.92% +2.15% +1.04% -0.73% -0.54% Change
More quotes
Financials (USD)
Sales 2021 2 831 M - -
Net income 2021 450 M - -
Net cash position 2021 2 027 M - -
P/E ratio 2021 42,2x
Yield 2021 -
Sales 2022 3 450 M - -
Net income 2022 779 M - -
Net cash position 2022 2 925 M - -
P/E ratio 2022 23,1x
Yield 2022 -
Capitalization 18 170 M 18 170 M -
EV / Sales 2021 5,70x
EV / Sales 2022 4,42x
Nbr of Employees 1 773
Free-Float 98,8%
More Financials
Company
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk... 
Sector
Biotechnology & Medical Research
Calendar
05/26
More about the company
Notations Surperformance© of Incyte Corporation
Trading Rating : Investor Rating :
More Ratings
All news about INCYTE CORPORATION
09:18aSECTOR UPDATE : Health Care Stocks Fall Premarket Monday
MT
08:25aINCYTE  : Late-Stage Studies on Ruxolitinib Cream as Potential Vitiligo Therapy ..
MT
08:17aINCYTE  : vitiligo treatment meets main goal in late-stage trial
RE
07:43aINCYTE  : vitiligo treatment meets main goal in late-stage trial
RE
07:31aINCYTE  : Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxo..
BU
05/12INCYTE  : Data From Incyte's Oncology Portfolio Accepted for Presentation at the..
BU
05/12INCYTE  : MorphoSys Dose First Patient in Late-Stage Study of Lymphoma Drug Cand..
MT
05/11PRESS RELEASE  : MorphoSys and Incyte Announce -3-
DJ
05/11PRESS RELEASE  : MorphoSys and Incyte Announce -2-
DJ
05/11PRESS RELEASE  : MorphoSys and Incyte Announce First Patient Dosed in Phase 3 fr..
DJ
05/10INCYTE  : Crescendo Biologics Names Incyte VP as Chief Financial Officer
MT
05/05PRESS RELEASE : MorphoSys AG Reports First Quarter -2-
DJ
05/05PRESS RELEASE : MorphoSys AG Reports First Quarter 2021 Results
DJ
05/04INCYTE  : Management's Discussion and Analysis of Financial Condition and Result..
AQ
05/04INCYTE  : Swings to Q1 Profit, Revenue Rises
MT
More news
News in other languages on INCYTE CORPORATION
02:23pINCYTE  : meldet positive Ergebnisse des Phase-3-Programms TRuE-V, in dem Ruxoli..
08:50aWALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
06:05aWALL STREET STOCK EXCHANGE : USA-Les valeurs à suivre à Wall Street (actualisé)
05/13INCYTE  : Daten aus dem Onkologieportfolio von Incyte für Präsentation auf dem v..
05/13INCYTE  : Données du portefeuille d'oncologie d'Incyte acceptées pour présentati..
More news
Analyst Recommendations on INCYTE CORPORATION
More recommendations
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 106,87 $
Last Close Price 82,62 $
Spread / Highest target 74,3%
Spread / Average Target 29,3%
Spread / Lowest Target -15,3%
EPS Revisions
Managers and Directors
NameTitle
Herve Hoppenot Chairman, President & Chief Executive Officer
Christiana Stamoulis Chief Financial Officer & Executive Vice President
Steven H. Stein Chief Medical Officer & Executive Vice President
Dashyant Dhanak Chief Scientific Officer & Executive VP
Paul A. Friedman Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION-5.01%18 170
MODERNA, INC.54.48%64 799
LONZA GROUP AG-0.81%46 408
IQVIA HOLDINGS INC.30.62%44 856
CELLTRION, INC.-24.65%32 736
SEAGEN INC.-15.78%26 768